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Pulmonary Artery Hypertension:
The Link Between Prostanoids
and Bloodstream Infections
Because of their vasodilatory and antiproliferative effects, the
administration of prostanoids has become an important part of
treatment for patients with pulmonary arterial hypertension
(PAH). The intravenous infusion of the 2 prostanoids, epoproste-
nol (epoprostenol sodium [brand name Flolan, Glaxo SmithKline,
Research Triangle Park, North Carolina]) and treprostinil (trepro-
stinil sodium [brand name Remodulin, United Therapeutics,
Silver Spring, Maryland]) are approved by the U.S. Food and Drug
Administration for use in patients with PAH and are commonly
used in many centers today. These drugs are discussed by Chin and
Rubin (1) in their review on the topic in a recent issue of the
Journal. However, there is no mention of the caution raised by a
study performed at 7 PAH centers during 2003 to 2006 by the
Centers for Disease Control and Prevention (CDC) on the
possible link between treprostinil and greater rates of bloodstream
infections (BSIs); (primarily gram-negative infections) when com-
pared with the use of intravenous epoprostenol (2). The overall
BSI pooled mean rate (per 1,000 medicine days) was 1.11 for
patients receiving treprostinil compared with 0.43 in those receiv-
ing epoprostenol (pooled incidence rate ratio: 2.57; 95% confi-
dence interval: 1.81 to 3.64). The pooled mean rate for gram-
negative BSIs was 0.76 among patients on treprostinil compared
with 0.06 in patients on epoprostenol (pooled incidence rate ratio:
12.77; 95% confidence interval: 6.55 to 26.80) (2). The CDC
noted that “health-care providers who care for PAH patients
should be aware of these findings.” The reasons for these observed
differences are unknown and may in part be related to the drug’s
differing anti-inflammatory effects. Therefore, further studies are
needed to determine the reason for the observed increased BSI rate
with treprostinil when compared with epoprostenol.
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Reply
W e thank Dr. Kapoor for his thoughtful letter regarding our article
(1). Bloodstream infections are an important complication of indwell-
ing catheters and, in this Centers for Disease Control and Prevention
(CDC) report, the overall infection rate with treprostinil was signif-
icantly greater than that of epoprostenol (incidence rate ratio 2.57,
95% confidence interval: 1.81 to 3.64). The rate of gram-negative
infections was also much greater with treprostinil, with gram-
negative infections actually more common than gram-positive
infections. This finding suggests that, when line infection is
suspected in patients receiving intravenous treprostinil, the empiric
use of antibiotics with both gram-positive and -negative coverage
should be considered until blood culture results are available.
However, these findings do not rise to the level of robust
scientific proof: First, just before the initiation of the study, an alert
letter from United Therapeutics (Silver Spring, Maryland), the
manufacturer of treprostinil, was distributed requesting that phy-
sicians report any gram-negative bacteremia cases for further
evaluation. Shortly after this concern was raised, the CDC asked
centers where treprostinil was used frequently to participate in a
more formal study. It is possible that centers with increased rates
of gram-negative infections were more likely to participate, par-
ticularly given the increased awareness prompted by the alert letter.
Second, there appeared to be significant heterogeneity within the
results, with incidence rate ratios for infections with treprostinil
compared with epoprostenol ranging from 0.59 to 3.90 across the
5 centers from which data were available for both medications.
Finally, data were collected retrospectively and over different years
at each site, the CDC was not directly involved in the data
collection at most sites, and the information was only presented as
a 2-page brief rather than a full, peer-reviewed research paper.
Thus, although the CDC report raises awareness to the risk and
provides guidance for the current treatment of suspected line
infections, additional formal study is required.
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